Eli Lilly's experimental obesity drug retatrutide delivered striking results in a late-stage trial, with patients on the highest dose losing an average of 25% of their body weight after 80 weeks and 30% after a 104-week extension. More than a third of participants lost 30% or more of their weight. The data, published in the New England Journal of Medicine, is likely to intensify competition in the rapidly growing obesity treatment market, where Lilly already sells the dual-acting drug tirzepatide under the brand names Zepbound and Mounjaro.
Retatrutide is a triple-acting drug that targets GLP-1, GIP, and glucagon receptors, building on the mechanisms of Novo Nordisk's semaglutide and Lilly's own tirzepatide. The trial also showed meaningful improvements in knee osteoarthritis pain, sleep apnea, blood pressure, and cholesterol. However, the study did not compare retatrutide directly against existing treatments, so its relative advantage over tirzepatide or semaglutide remains unproven.
For Lilly, the results reinforce its lead in the next generation of obesity therapies, but the lack of a head-to-head trial leaves open questions for regulators and payers. The company will need to show whether the added potency translates into better real-world outcomes without new safety concerns. The most common side effects were transient gastrointestinal issues, and a small number of cardiovascular events were reported across both drug and placebo groups.